The oral-cannabis review described differing results when oil and decoction preparations were compared. One pilot’s findings came from a single person, limiting any claim that one preparation invariably produces higher exposure.
The reviewed comparisons differed
One published comparison reported greater availability of CBDA after decoction and greater availability of THC and its metabolites after oil. A separate pilot reported higher peak values for several cannabinoids after decoction, but supplied data from only one participant.
The review summarized separate small comparisons, rather than a pooled randomized oil-versus-tea trial. The review emphasized variation in preparation content and recovered cannabinoid exposure.
Preparation differences complicate a ranking
Oil and tea are categories, not chemically identical products. Cannabinoid composition, delivered amounts and preparation procedures can differ. A peak concentration comparison involving one person cannot establish which preparation will yield the higher exposure in a broader patient population. Opposing observations also do not justify averaging unmatched products into an individual conversion.
What the review supports
The evidence supports retaining formulation and study details when interpreting oral exposure. It does not supply a universal oil-to-tea dose equivalence or establish that one form is consistently safer. Peak plasma or serum measurements remain exposure findings; they are not direct demonstrations of a predictable level of impairment or therapeutic success.
Related reading: limits of identifying cannabis sources.
Research cited
Poyatos and colleagues (2020). Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. DOI: 10.3390/medicina56060309.
Leave a Reply